Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
Artiva Biotherapeutics (Nasdaq: ARTV) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 1:10 p.m. EST in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Artiva Biotherapeutics (Nasdaq: ARTV) announced management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 4, 2026 at 1:10 p.m. EST in Boston.
Artiva management will meet registered investors and the audio webcast plus archived recording will be available on the company investor website for 90 days.
Details
News Market Reaction – ARTV
On Feb 25, the day this news came out, ARTV closed 0.20% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
Key Figures
- Conference date
- March 4, 2026
- TD Cowen 46th Annual Health Care Conference fireside chat
- Session time
- 1:10 p.m. EST
- Scheduled time for Artiva’s fireside chat
- Replay window
- 90 days
- Archived audio webcast availability on Artiva’s website
- Conference number
- 46th Annual
- TD Cowen Health Care Conference edition
- Current share price
- $5.02
- Price before this conference participation news
- 1-day move
- 4.58%
- Price change over the prior 24 hours
- 52-week range
- $1.47 – $7.36
- Positioned 31.79% below high and 241.5% above low
- Shelf expiry
- 2028-08-06
- Expiration date of active S-3 shelf registration
Historical Context
-
New CFO hire with RSU grant and experience to support upcoming milestones.
-
Appointment of experienced biopharma executive to the board of directors.
-
Announcement of cost-effectiveness and durability data presentations for AlloNK.
-
NanoSyrinx CEO appointment associated with ARTV but followed by slight share decline.
-
Positive initial safety and translational data for AlloNK in autoimmune disease.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.
Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference.
To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK® (also known as AB-101), is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK is currently being evaluated in three ongoing clinical trials for the treatment of B-cell driven autoimmune diseases, including a company-sponsored basket trial across autoimmune diseases that includes rheumatoid arthritis and Sjögren’s disease and an investigator-initiated basket trial in B-cell driven autoimmune diseases. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts:
Investors
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com
Media
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
Source: Artiva Biotherapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.